Moderna/MRNA

$153.55

-7.84%
-
1D1W1MYTD1YMAX

About Moderna

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.

Ticker

MRNA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Stephane Bancel

Employees

5,600

Headquarters

Cambridge, United States

Moderna Metrics

BasicAdvanced
$64B
Market cap
-
P/E ratio
-$15.66
EPS
1.60
Beta
-
Dividend rate
$64B
1.59893
$170.47
$62.55
4M
4.034
3.91
4.486
4.486
-29.22%
-37.68%
-34.13%
12.391
4.979
5.019
-65.78%
-235.33%
104.27%

What the Analysts think about Moderna

Analyst Ratings

Majority rating from 26 analysts.
Buy

Price Targets

Average projection from 20 analysts.
10.39% downside
High $310.00
Low $60.00
$153.55
Current price
$137.59
Average price target

Moderna Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-703.59% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$167M
-94.06%
Net income
-$1.2B
-641.47%
Profit margin
-703.59%
-9,225.68%

Moderna Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 14.36%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$3.62
-$9.53
$0.55
-$3.07
-
Expected
-$4.04
-$1.93
-$0.97
-$3.58
-$3.36
Surprise
-10.4%
394.47%
-156.6%
-14.36%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Moderna stock?

Moderna (MRNA) has a market cap of $64B as of May 28, 2024.

What is the P/E ratio for Moderna stock?

The price to earnings (P/E) ratio for Moderna (MRNA) stock is 0 as of May 28, 2024.

Does Moderna stock pay dividends?

No, Moderna (MRNA) stock does not pay dividends to its shareholders as of May 28, 2024.

When is the next Moderna dividend payment date?

Moderna (MRNA) stock does not pay dividends to its shareholders.

What is the beta indicator for Moderna?

Moderna (MRNA) has a beta rating of 1.6. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Moderna stock price target?

The target price for Moderna (MRNA) stock is $137.59, which is 10.39% below the current price of $153.55. This is an average based on projections from 20 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Moderna stock

Buy or sell Moderna stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing